Legend Biotech
LEGN
208 hedge funds and large institutions have $4.44B invested in Legend Biotech in 2024 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 70 increasing their positions, 71 reducing their positions, and 16 closing their positions.
169% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 16
15% more funds holding
Funds holding: 181 → 208 (+27)
9% more capital invested
Capital invested by funds: $4.06B → $4.44B (+$385M)
0.13% less ownership
Funds ownership: 25.17% → 25.04% (-0.13%)
1% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 71
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
49% less call options, than puts
Call options by funds: $12.2M | Put options by funds: $23.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$121M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$37.7M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$26.3M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$16.7M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$15.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$65.3M |
| 2 |
Millennium Management
New York
|
-$58M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$53.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$41.2M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$17.6M |
LEGN Hedge Fund Activity: Q3 2024 in Review
208 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q3 2024, worth a combined $4.44B — up 9.5% from $4.06B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new LEGN positions and 16 closed out — a net gain of 27 holders — while 70 added to existing stakes and 71 trimmed.
The largest buyer was Invesco, adding an estimated $121M. The largest seller was BlackRock, cutting an estimated $65.3M.
- 208 institutional investors held Legend Biotech (LEGN) as of Q3 2024, up from 181 in Q2 2024.
- Funds reported $4.44B of Legend Biotech stock for Q3 2024, up 9.5% quarter-over-quarter.
- 43 funds opened new Legend Biotech positions in Q3 2024 and 16 closed out, a net change of +27 holders.
- The largest Legend Biotech buyer in Q3 2024 was Invesco, an estimated $121M added.
- The largest Legend Biotech seller in Q3 2024 was BlackRock, an estimated $65.3M sold.
Based on aggregated 13F filings for Q3 2024.